Naproxcinod Must Show More Data On Both Safety And Therapeutic Benefit After "Complete Response" Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA tells NicOx it wants long-term studies on drug's cardiovascular and gastrointestinal safety, but no additional efficacy trials.